Spatial and temporal organization of the genome: Current state and future aims of the 4D nucleome project
- PMID: 37419111
- PMCID: PMC10528254
- DOI: 10.1016/j.molcel.2023.06.018
Spatial and temporal organization of the genome: Current state and future aims of the 4D nucleome project
Abstract
The four-dimensional nucleome (4DN) consortium studies the architecture of the genome and the nucleus in space and time. We summarize progress by the consortium and highlight the development of technologies for (1) mapping genome folding and identifying roles of nuclear components and bodies, proteins, and RNA, (2) characterizing nuclear organization with time or single-cell resolution, and (3) imaging of nuclear organization. With these tools, the consortium has provided over 2,000 public datasets. Integrative computational models based on these data are starting to reveal connections between genome structure and function. We then present a forward-looking perspective and outline current aims to (1) delineate dynamics of nuclear architecture at different timescales, from minutes to weeks as cells differentiate, in populations and in single cells, (2) characterize cis-determinants and trans-modulators of genome organization, (3) test functional consequences of changes in cis- and trans-regulators, and (4) develop predictive models of genome structure and function.
Keywords: 4D nucleome; cell cycle; chromosome folding; development; disease model; genomics technologies; imaging technologies; modeling; nuclear organization.
Copyright © 2023 Elsevier Inc. All rights reserved.
Conflict of interest statement
Declaration of interests J.D. is on the Scientific Advisory Board of Arima Genomics (San Diego, CA) and Omega Therapeutics (Cambridge, MA). F.A. is a shareholder of EarlyDiagnostics, Inc. S.A. is a member of the Chao-Ting Wu laboratory and holds or has patent filings pertaining to imaging and has held a sponsored research agreement with Bruker Inc. L.B. is a co-founder and scientific advisor of Stylus Medicine (Cambridge, MA). W.L. is a co-founder of Hub Biosciences. B.R. is a co-founder of and member of the Scientific Advisory Board of Arima Genomics (San Diego, CA) and a co-founder of Epigenome Technologies (San Diego, CA). J.S. is a Scientific Advisory Board member, consultant, and/or co-founder of Cajal Neuroscience, Guardant Health, Maze Therapeutics, Camp4 Therapeutics, Phase Genomics, Adaptive Biotechnologies, Scale Biosciences, Sixth Street Capital, Pacific Biosciences, and Prime Medicine. X.S. is a co-founder of Granule Therapeutics (San Francisco, CA). S.Z. is a founder and board member of Genemo, Inc (San Diego, CA).
Figures
References
Publication types
MeSH terms
Substances
Grants and funding
- UM1 HG011586/HG/NHGRI NIH HHS/United States
- UM1 HG011536/HG/NHGRI NIH HHS/United States
- U01 HL156056/HL/NHLBI NIH HHS/United States
- U54 DK107980/DK/NIDDK NIH HHS/United States
- R01 HD091797/HD/NICHD NIH HHS/United States
- U01 DK127422/DK/NIDDK NIH HHS/United States
- U01 DK127419/DK/NIDDK NIH HHS/United States
- U01 DK127421/DK/NIDDK NIH HHS/United States
- U01 DA052713/DA/NIDA NIH HHS/United States
- UM1 HG011585/HG/NHGRI NIH HHS/United States
- U01 DK127405/DK/NIDDK NIH HHS/United States
- U01 CA260851/CA/NCI NIH HHS/United States
- U01 CA200147/CA/NCI NIH HHS/United States
- UM1 HG011593/HG/NHGRI NIH HHS/United States
- U01 DK127429/DK/NIDDK NIH HHS/United States
- DP2 GM140938/GM/NIGMS NIH HHS/United States
- P30 CA008748/CA/NCI NIH HHS/United States
- U01 HL156059/HL/NHLBI NIH HHS/United States
- U01 DA052715/DA/NIDA NIH HHS/United States
- RM1 HG011016/HG/NHGRI NIH HHS/United States
- U01 DK128852/DK/NIDDK NIH HHS/United States
- U01 CA200059/CA/NCI NIH HHS/United States
- U01 HL157989/HL/NHLBI NIH HHS/United States
